General
Preferred name
surufatinib
Synonyms
HMPL-012 ()
VEGFR2 inhibitor [WO2011060746] ()
KDR-IN-1 ()
Sulfatinib ()
HMPL-012, Sufatinib, Surfatinib, Surufatinib ()
P&D ID
PD064933
CAS
1816307-67-1
1308672-74-3
Tags
available
drug
Drug indication
Neuroendocrine cancer
Solid tumour/cancer
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Surufatinib is an oral tyrosine kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, to inhibit key angiogenic and immune pathways in solid tumours. Surufatinib's chemical structure is claimed in patent WO2011060746, and its use as a potential anti-angiogenic agent is included . In this patent it is referred to as 'Compound of Formula A'. (GtoPdb)
Compound Sets
11
Cayman Chemical Bioactives
34206
ChEMBL Drugs
CHEMBL4297190
Drug Repurposing Hub
DrugBank
DB15106
DrugMAP
DMPOTM4
Guide to Pharmacology
9769
MedChem Express Bioactive Compound Library
HY-12297
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
sulfatinib
TargetMol Bioactive Compound Library
T4075
External IDs
16
Properties
(calculated by RDKit )
Molecular Weight
480.19
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
4
cLogP
3.78
TPSA
112.24
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.32
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Angiogenesis
JAK/STAT Signaling
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Target
FGFR1
HERG
KDR
FGFR
VEGFR
CSF-1R,FGFR,VEGFR
MOA
tyrosine kinase inhibitor
Source data